Subscribe
Core coverageRVMD

Company profile / RVMD

Revolution Medicines

Clinaptis stanceNeutral
ConvictionMedium
Ticker
RVMD
Exchange
NASDAQ
Coverage
Standard profile
Updated
Sep 23, 2026
Oncology / RAS

Commercial-stage precision-oncology company building a portfolio of RAS(ON) inhibitors. Its first product, RASONQUE (daraxonrasib), is approved in the U.S. for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy or for patients who are not candidates for multiagent systemic therapy. The broader value case rests on moving daraxonrasib into first-line and adjuvant pancreatic cancer and previously treated RAS-mutant non-small cell lung cancer, while advancing mutation-selective inhibitors across G12D, G12C and G12V tumors.

01 / Clinaptis view

The current read

Initial read: RASONQUE has crossed the two hardest near-term gates—a decisive Phase 3 result and a broad U.S. approval that does not require a companion diagnostic. In RASolute 302, median overall survival was 13.2 months versus 6.7 months for chemotherapy, with an overall-survival hazard ratio of 0.40 and a progression-free-survival hazard ratio of 0.49 in the intent-to-treat population.

  1. The first commercial setup is credible: once-daily oral dosing, immediate U.S. availability and a $39,800 wholesale acquisition cost for a 30-day supply. The stock thesis is now an execution-and-expansion thesis.
  2. Initial prescriptions, payer access, treatment duration, dose intensity and dermatologic management will establish the value of the approved business. The larger upside requires daraxonrasib to work earlier in pancreatic cancer and in RAS-mutant lung cancer, with mutation-selective agents adding breadth rather than merely duplicating the lead asset.
  3. At $192.86 per share and roughly $40.7 billion of equity value on September 23, the valuation already capitalizes far more than a successful later-line pancreatic launch. The June balance sheet provides substantial development capacity—approximately $3.94 billion of cash, equivalents and marketable securities—but investors should not treat that as unencumbered net cash.
  4. Revolution also carried a $487 million convertible-note liability and a $549 million future-royalty liability at quarter-end, and approval triggered a required $250 million secured term-loan draw unless the facility had previously been terminated.
02 / Consensus gap

Where the market may differ

The market may be correctly enthusiastic about the clinical profile and still be too generous on the speed and breadth of monetization. The approved population is meaningful, but pancreatic-cancer attrition between first- and second-line treatment constrains the immediately addressable pool.

  1. The differentiating questions are now whether the survival result produces a fast, durable launch; whether first-line pancreatic and NSCLC Phase 3 studies reproduce the lead asset's differentiation; whether zoldonrasib, elironrasib and RMC-5127 create non-overlapping value; and how much of that expansion is already embedded in a roughly $40.7 billion equity value. The label also makes tolerability a commercial variable rather than a footnote: dermatologic toxicity occurred in 86% of patients and was Grade 3 in 10%, alongside warnings for oral disorders, diarrhea, gastrointestinal perforation and interstitial lung disease or pneumonitis.
  2. The clean debate is therefore no longer approval versus rejection. It is launch velocity, duration, expansion probability and portfolio economics after accounting for the convertible notes, required borrowing and tiered synthetic-royalty burden.
Coverage state
Standard profile
What the review turns on
Key variable

Whether RASONQUE converts its decisive later-line pancreatic-cancer survival result into a fast, durable U.S. launch while first-line pancreatic and NSCLC Phase 3 programs validate enough expansion value to support the current valuation

Next catalyst

RASONQUE · First U.S. launch indicators—access, prescriptions, duration, dose modification and discontinuation · next quarterly update; Daraxonrasib · RASolve 301 enrollment completion and 2027 initial readout timing

03 / Pipeline

Key programs

5 assets · 6 programs

AssetIndicationStageNext event
RASONQUE / daraxonrasib
Metastatic pancreatic adenocarcinoma after prior systemic therapy, or patients not eligible for multiagent therapy
Approved · Aug 26
First launch evidenceAccess, prescriptions, duration, dose modifications and discontinuations.
Daraxonrasib
First-line metastatic pancreatic adenocarcinoma
Ph3 · first line
RASolute 303 executionEnrollment, efficacy and combination tolerability; registrational timing not yet confirmed.
Previously treated RAS-mutant metastatic NSCLC
Ph3 · enrolling
2027 · RASolve 301 readoutEnrollment completion, efficacy, durability and tolerability.
Zoldonrasib (RMC-9805)
RAS G12D pancreatic and lung cancers
Ph1/2 + Ph3
Combination and Phase 3 updatesDurability, tolerability and asset differentiation.
Elironrasib (RMC-6291)
RAS G12C tumors
Ph1/2 · Ph3 planned
4Q26 · Phase 3 initiationFinal design, combinations and differentiation versus established G12C therapy.
RMC-5127
RAS G12V tumors
Ph1
Early clinical updateDose selection, safety and response durability.
04 / Connected research

Published on RVMD

View full archive
  1. 01

    Pancreatic Cancer Had No Druggable Target. Now It Does

    Daraxonrasib in 2L PDAC: When the Data Actually Deliver

    Read